No abstract

Dyspnea is deemed to result from an imbalance between ventilatory demand and capacity. The single-breath diffusing capacity for carbon monoxide (DLCO) is often the best correlate to dyspnea in COPD. We hypothesized that DLCO contributes to the assessment of ventilatory demand, which is linked to physiological dead space /tidal volume (V(D)/V(T)) ratio. An additional objective was to assess the validity of non-invasive measurement of transcutaneous P(CO2) allowing the calculation of this ratio. Forty-two subjects (median [range] age: 66 [43-80] years; 12 females) suffering mainly from moderate-to-severe COPD (GOLD stage 2 or 3: n = 36) underwent pulmonary function and incremental exercise tests while taking their regular COPD treatment. DLCO% predicted correlated with both resting and peak physiological V(D)/V(T) ratios (r = -0.55, p = 0.0015 and r = -0.40, p = 0.032; respectively). The peak physiological V(D)/V(T) ratio contributed to increase ventilation (increased ventilatory demand), to increase dynamic hyperinflation and to impair oxygenation on exercise. Indirect (MRC score) and direct (peak Borg score/% predicted VO(2)) exertional dyspnea assessments were correlated and demonstrated significant relationships with DLCO% predicted and physiological V(D)/V(T) at peak exercise, respectively. The non-invasive measurement of transcutaneous P(CO2) both at rest and on exercise was validated by Bland-Altman analyses. In conclusion, DLCO constitutes and indirect assessment of ventilatory demand, which is linked to exertional dyspnea in COPD patients. The assessment of this demand can also be non invasively obtained on exercise using transcutaneous PCO(2) measurement.

BackgroundATS/ERS Task Force has highlighted that special attention must be paid when FEV1 and FVC are concomitantly decreased (<5th percentile) and the FEV1/FVC ratio is normal (>5th percentile) because a possible cause of this non specific pattern (NSP) is collapse of small airways with normal TLC measured by body plethysmography (>5th percentile). Our objectives were to determine the main lung diseases associated with this pattern recorded prospectively in a lung function testing (LFT) unit, the prevalence of this pattern in our LFT and among the diseases identified, and its development.MethodsObservational study of routinely collected data selected from our Clinical Database Warehouse.ResultsThe prevalence of NSP was 841/12 775 tests (6.6%, 95% CI: 6.2 to 7.0%). NSP was mainly associated with seven lung diseases: asthma (prevalence of NSP among asthmatics: 12.6%), COPD/emphysema (prevalence 8.6%), bronchiectasis (12.8%), sarcoidosis (10.7%), interstitial pneumonia (4.0%), pulmonary hypertension (8.9%) and bilateral lung transplantation for cystic fibrosis (36.0%). LFT measurements were described in 185 patients with NSP and indisputable nonoverlapping causes. A moderate defect (FEV1: 66 ± 9% predicted) with mild lung hyperinflation (FRC: 111 ± 27%, RV: 131 ± 33% predicted: suggesting distal airway obstruction) was evidenced whatever the underlying cause. A long term stability of NSP was evidenced in 130/185 patients (70% 95% CI: 64 to 77%).ConclusionsNSP is observed in asthma, COPD/emphysema, bronchiectasis, sarcoidosis, pulmonary hypertension, interstitial pneumonia and after bilateral lung transplantation and remains stable in the majority of patients.